A study to assess the safety and tolerability of single doses of AZD4076 in healthy male subjects

Study identifier:D5590C00001

ClinicalTrials.gov identifier:NCT02612662

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A randomized, single-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of AZD4076 tetracosasodium following single-ascending dose administration to healthy male subjects

Medical condition

Non-alcoholic steatohepatitis (NASH)

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4076, Placebo

Sex

Male

Actual Enrollment

40

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 24 Nov 2015
Primary Completion Date: 04 Nov 2017
Estimated Study Completion Date: 16 Aug 2024

Study design

Allocation: Randomized
Endpoint Classification: Safety
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Feb 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria